MONTREAL, CANADA and MEXICO CITY, MEXICO--(MARKET WIRE)--Jul 16, 2007 -- ProMetic BioSciences Inc., the drug development subsidiary of ProMetic Life Sciences Inc. (“ProMetic”) (Toronto:PLI.TO - News), and Laboratorios Dermatologicos Darier S.A. (“Darier”), the market leader in dermatology in Mexico, announced they have signed an agreement for ProMetic’s synthetic anti-inflammatory compound PBI-1308 in dermatological disorders. PBI-1308, a novel compound which derives from ProMetic’s autoimmune disease and inflammation program, has demonstrated in vivo efficacy in animal models of atopic dermatitis and psoriasis when orally or topically administered.
